Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared to Cytotoxic Chemotherapy

There is increasing evidence that rates of atrial arrhythmias (AA), specifically atrial fibrillation and flutter are elevated in patients treated with the tyrosine kinase inhibitor, ibrutinib, however the exact risk of ibrutinib-associated AA is not definitively established. We conducted a retrospective study of 137 patients diagnosed with B-cell malignancies treated with ibrutinib compared to 106 patients treated with chemotherapy for the same cancers in order to quantify the rates and risk of AA in a “real-world” sample of cancer patients. Fisher's exact test was used to evaluate for any statistically significant differences between groups.

Source: The American Journal of Cardiology - May 24, 2019 Category: Cardiology Authors: Michael G. Fradley, Matthew Gliksman, Josephine Emole, Federico Viganego, Isaac Rhea, Allan Welter-Frost, Merna Armanious, Dae Hyun Lee, Christine Walko, Bijal Shah, Julio C. Chavez, Howard McLeod, Javier Pinilla-Ibarz, Matthew B. Schabath Source Type: research